MedPath

To study the efficacy of Dhanyaka-gokshuradi ghrita in comparison with Tamsulosin hydrochloride for the treatment of benign enlargement of prostate

Phase 2
Completed
Conditions
Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptoms
Registration Number
CTRI/2020/12/029728
Lead Sponsor
Dr Sayali Babasaheb Gore
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
60
Inclusion Criteria

•A known diagnosed case of (benign enlargement of prostate) on the basis of clinical and investigative methods.

•Male patient of age group more than 40 -60 yrs. Irrespective of religion and occupation.

•Prostate size below 35 gms

Exclusion Criteria

• Acute/chronic retention of urine, stone formation, renal failure.

•Bladder neck stenosis, bladder diverticulum, neurogenic bladder, neoplasm of bladder, urethral stricture.

•CA prostate, Prostitis.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1)Benign enlargement of prostate is one of the most common diseases in ageing men and most common cause of lower urinary tract symptoms_ <br/ ><br>The prevalence of BEP increases after the age of 40 years. Genetics, diet and life style also Contributes for BEP. <br/ ><br>2)To evaluate the and establish safer,cost-effective Dhanyaka-gokshuradi ghrita in the management of benign enlargement of prostate-[management of benign enlargement of prostate]Timepoint: Duration of treatment 21days total
Secondary Outcome Measures
NameTimeMethod
Dhanyaka-gokshuradi ghrita is effective the management of benign enlargement of prostate-[management of benign enlargement of prostate]Timepoint: 21 days study with 4 follow up <br/ ><br>(0,7,14,21 days) <br/ ><br> <br/ ><br> <br/ ><br> <br/ ><br> <br/ ><br>
© Copyright 2025. All Rights Reserved by MedPath